Cytos Biotechnology AG / Key word(s): AGM/EGM
03.04.2014 15:14

Release of an ad hoc announcement pursuant to Art. 53 KR

---

Annual Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approve all resolutions

Schlieren (Zurich), Switzerland, 3 April 2014 - Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved all resolutions at the Annual Shareholders' Meeting 2014.
The Annual Shareholders' Meeting of Cytos Biotechnology Ltd took place at the company's headquarters in Schlieren (Zurich), Switzerland. It was attended by 51 shareholders. 14,496,488 shares or 47.5% of a total of 30,525,276 shares were represented.

For further information, please contact: 

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
e-mail: harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma.

CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

www.cytos.com

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, including that CYT003 may not demonstrate safety or efficacy in clinical trials, that there may be delays in development or that CYT003 may not receive marketing approval, and that the Company relies on outside financing to meet capital requirements, which may not be available under acceptable terms or at all. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.



+++++
Additional features:
Document: http://n.equitystory.com/c/fncls.ssp?u=NEOXQFWGLY Document title: Cytos_Press_E_140403.pdf


03.04.2014 News transmitted by EQS Schweiz AG. 
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1'300 listed companies. 
The Swiss news archive can be found at www.equitystory.ch/news

---

 
Language:               English
Company:                Cytos Biotechnology AG
                        Wagistr. 25
                        8952 Schlieren
                        Switzerland
Phone:                  +41 44 733 4747
Fax:                    +41 44 733 4740
E-mail:                 info@cytos.com
Internet:               www.cytos.com
ISIN: CH0011025217, CH0029060735 Valor:                  -
Listed: Freiverkehr in Berlin, München, Stuttgart; Frankfurt in Open Market ; SIX  
End of Announcement EQS Group News-Service  

---